This document provides information about an upcoming conference on pain therapeutics taking place from May 22-24, 2017 in London. It summarizes the conference agenda, speakers, and topics to be discussed over the two day event and half day workshop. Key highlights include: - The conference will focus on strategies for pain management, evaluating translation between pre-clinical and clinical studies, assessing animal models for studying pain pathways, and examining new case studies from pharmaceutical companies. - Speakers will address topics like CGRP receptor antagonists for migraine, developing novel pain treatments, using veterinary trials to inform human research, biomarkers for pain pathways, and new therapeutic approaches for pain including Kappa opioid receptor agonists. -

1. REGISTER BY 31ST JANUARY AND SAVE £400
REGISTER BY 28TH FEBRUARY AND SAVE £200
REGISTER BY 31ST MARCH AND SAVE £100
PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 24th May 2017, Copthorne Tara Hotel, London, UK
www.pain-therapeutics.co.uk
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
@SMIPHARM
#painsmi
Animal Models of Pain: A Critical Assessment
8.30 - 12.30
Workshop Leader:
Dr Steven G. Kamerling, Senior Research Director and Therapeutic Area Head for Pain,
Inflammation, Oncology and Cardiac Disease, Global Therapeutics Research, Zoetis
Assess the latest developments and innovations
in effective and safe pain management
SMi Presents the 17th Annual Conference on...
Copthorne Tara Hotel, London, UK
Pain Therapeutics
CONFERENCE:
22ND - 23RD
WORKSHOP: 24TH
MAY
2017
“A very informative and interactive
conference!” DELEGATE 2016
“I’ll attend this conference again
if I’ll be able to” DELEGATE 2016
Sponsored by REASONS TO ATTEND:
• Strategies and real case studies to minimise risk of opioid
dependence
• Evaluate the translation gap with case studies from a
pre-clinical and clinical perspective
• Assess the latest case studies from top pharma companies
in the multi-faceted area of pain for 2017
• Examine the use of animal models to study pain pathways
CHAIRS FOR 2017:
• Prof Anthony Jones, Professor of Neuro-Rheumatology,
University of Manchester
• Dr Steven Kamerling, Therapeutic Area Head for Pain,
Inflammation and Oncology, Zoetis
• Dr Joseph W. Stauffer, Chief Medical Officer,
Cara Therapeutics, Inc.
KEYNOTE SPEAKERS INCLUDE:
• Dr Stephen Doberstein, Senior Vice President and Chief
Scientific Officer, Nektar Pharmaceuticals
• Dr Iain Chessell, Head of Neuroscience, AstraZeneca
• Dr Randall Stevens, Chief Medical Officer, Centrexion
Therapeutics Corp.
• Dr Richard Butt, Chief Executive Officer, Apollo Therapeutics
• Prof Theo Meert, Head of Global Government Grant Office,
Janssen Pharmaceutica NV
• Dr Thomas Klein, Associate Director Translational Science,
Mundipharma Research
• Dr Tanja Ouimet, Head of Clinical Operations, Pharmaleads
• Dr Narender Gavva, Scientific Director, Amgen
• Dr Thomas Christoph, Head of Pharmacology and Biomarker
Development, Grunenthal GmbH
• Dr Ian Bell, Principal Scientist, MSD, USA

2. Pain Therapeutics
Day One | Monday 22nd May 2017 www.pain-therapeutics.co.uk
8.30 Registration & Coffee
9.00 Chairman’s Session Opening Remarks
Prof Anthony Jones, Professor of Neuro-Rheumatology,
University of Manchester
OPENING KEYNOTE ADDRESS
9.10 Challenges in the development of novel pain treatment
options
• Conflicts in pain research
• Conflicts in economic value
• Conflicts in using compound
• Opioid addiction
Prof Theo Meert, Head of Global Government Grant Office,
Janssen Pharmaceutica NV
KEYNOTE ADDRESS
9.50 CGRP receptor antagonists for the treatment of migraine
Migraine is a highly disabling disorder that poses a significant
societal burden. Blockade of the CGRP receptor has been
shown to be effective for both acute and preventive treatment
of this neurovascular headache. This presentation will describe
the most recent clinical candidates discovered at MSD
• CGRP receptor antagonists have demonstrated clinical
efficacy for acute treatment of migraine
• Strategy for reducing the risk of hepatotoxicity
• Discovery and profile of the current clinical candidates
Dr Ian Bell, Principal Scientist, MSD, USA
10.30 Morning Coffee
11.00 The utility of early pharmacodynamics testing in pain drug
development
• Failure rate of new analgesic compounds in phase II is
notoriously high. Determining pharmacodynamic effects of
novel drugs in healthy subjects prior to moving to patient
studies can reduce risk by proving pharmacology and
aiding in dose selection
• We performed three studies with three different potentially
analgesic compounds in healthy subjects, using the
PainCart, a multimodal pain test battery
• Each of the studies had a randomized 4- or 5-way cross-
over design and was double-blind, placebo- and active
comparator controlled
• The compounds that were tested included an ␣2/3 subunit
selective GABA-A receptor agonist, a pan-Trk inhibitor, and
a selective Nav1.7 sodium channel blocker. The positive
controls were pregabalin and ibuprofen
• The studies were performed in parallel to phase II studies
in patients and aimed to test the correlation between
efficacy of the compounds in evoked pain test models and
efficacy in patients with clinical pain
• Results of each of the three PainCart studies will be
presented at the meeting
Dr Geert Jan Groeneveld, Research Director,
Centre for Human Drug Research
Dr Richard Butt, Chief Executive Officer, Apollo Therapeutics
11.40 Patient stratification based on somatosensory phenotyping:
Implications for mechanism-based pain treatment and drug
development
• Quantitative Sensory Testing (QST)
• Interpretation of sensory profiles
• Correlation between sensory profiles and treatment
efficacy
Dr Thomas Klein, Associate Director Translational Science,
Mundipharma Research
12.20 Networking Lunch
1.25 Brain mechanisms of vulnerability and resilience to pain:
Who controls the magic?
• What happens in the brain when we are in pain?
• What makes us more or less susceptible to pain?
• How can we use this information to understand current
treatments and develop new brain-based therapies?
Prof Anthony Jones, Professor of Neuro-Rheumatology,
University of Manchester
2.05 Chairman’s Session Opening Remarks
Dr Steven Kamerling, Therapeutic Area Head for Pain,
Inflammation and Oncology, Zoetis
KEYNOTE ADDRESS
2.10 How veterinary trials inform human analgesic drug
development
The assessment and alleviation of pain in companion animals is
an important component of veterinary medicine. Companion
dogs spontaneously develop painful diseases similar to those in
humans, such as osteoarthritis, cancer, and neuropathies. An
increasing number of human pharmaceutical companies are
turning to veterinary medicine for proof of concept studies to
assess novel drug targets
• What are the similarities in pain states between dogs and
humans and how are they assessed?
• What veterinary trials have been conducted on novel
pain therapies and how have they informed human drug
development?
• What advantages and disadvantages do veterinary trials
have compared to preclinical assessment in rodent pain
models?
Dr Steven Kamerling, Therapeutic Area Head for Pain,
Inflammation and Oncology, Zoetis
2.50 Afternoon Tea
3.20 Translational pain research
A growing number of clinical candidates for the treatment
of pain failed in clinical POC. How does the industry react to
decrease attrition?
• Potential and limitations of animal studies
• From animals to human tissue
• How to improve our screening tools
Dr Thomas Christoph, Head of Pharmacology and Biomarker
Development, Grunenthal GmbH
4.00 Improving the translatability of neurophysiological
pharmacodynamic biomarkers in pain pathways
• The need for translatable pharmacodynamic biomarkers in
drug discovery
• Neurophysiological biomarkers for drug targets in different
compartments of the pain pathways; a preclinical
perspective
• How a new IMI2 call aims to clinically validate these
neurophysiological biomarkers in healthy subjects
Dr Keith Phillips, Senior Research Scientist, Lilly UK
4.40 Chairman’s Closing Remarks and Close of Day One
DRUG DEVELOPMENT, FORMULATION & MECHANISMS
TRANSLATIONAL APPROACH & ANIMAL MODELS
Register online at www.pain-therapeutics.co.uk
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking
opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join
the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Since 1987, CHDR has developed into a unique research organisation
specialising in early phase studies which combines knowledge and
academic collaborations with operational excellence in clinical trial
services. CHDR’s strong track record in analgesic and pain research
allows us to offer an efficient route towards proof of concept in patients.
www.chdr.nl
Sponsored by Official Media Partner: Official Publications

3. Pain Therapeutics
www.pain-therapeutics.co.uk Day Two | Tuesday 23rd May 2017
OPIOID ADDICTION
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Dr Joseph Stauffer, Chief Medical Officer,
Cara Therapeutics, Inc.
OPENING ADDRESS
9.10 Kappa Opioid Receptor Agonists (KORA’S): A novel
approach to managing acute and chronic pain
• Review of the kappa opioid class
• Human abuse liability data of CR845 a novel KORA
• Post-operative and chronic pain data of CR845
Dr Joseph Stauffer, Chief Medical Officer,
Cara Therapeutics, Inc.
KEYNOTE ADDRESS
9.50 NKTR-181: Separating analgesia from euphoria in a novel
opioid agonist for chronic pain
Traditional mu-opioid agonists can have excellent analgesic
properties, but are typically associated with high abuse
liability that can lead to addiction and dependence. Recent
research has associated the rate of molecular entry across the
blood brain barrier with increased abuse liability in preclinical
species. Novel opioids that have greatly reduced rates of
entry into the CNS separate the euphorigenic effects from the
analgesic effects of CNS receptor engagement, raising the
prospect of an inherently low-abuse liability opioid analgesic,
independent of formulation or route of administration.
• Drugs of abuse: Relationship of brain entry rate to euphoria
and reinforcing behavior
• Engineering brain entry rate of MOR agonists to reduce
euphoria and abuse liability
• Preclinical analysis of brain transport rate, dopamine
release, and reinforcing behavior
• Clinical analysis of human abuse liability of NKTR-181,
a novel opioid agonist with inherently slow CNS entry
Dr Stephen Doberstein, Senior Vice President and Chief
Scientific Officer, Nektar Pharmaceuticals
10.30 Morning Coffee
11.00 Enhancing endogenous opioid concentrations as a novel
treatment for severe pain
Enkephalins are highly potent opioids produced and released
endogenously at the site of a painful stimulus. As they are
rapidly degraded by two metalloproteases, aminopeptidase
N (APN) and Neprilysin (NEP), the actions these opioid peptides
are very short lived. Animal studies have shown that inhibiting
the breakdown of enkephalins by inhibiting both NEP and APN
produces significant analgesia. PL37 and PL265 are the first
Dual ENKephalinase Inhibitors (DENKIs) to reach the clinic
• MoA of the Dual ENKephalinase Inhibitors (DENKIs)
• Clinical results obtained with PL37
• Clinical development of PL265
Dr Tanja Ouimet, Head of Clinical Operations, Pharmaleads
KEYNOTE ADDRESS
11.40 Exploiting synergy in the neurotrophin pathway to provide
analgesia
• Opportunity to expand efficacy of anti-NGFs to
neuropathic pain
• Unexpected synergy between blockade of NGF and
inflammatory pathways
• Significant analgesia in preclinical models at suppression
of NGF <10 %
Dr Iain Chessell, Head of Neuroscience, AstraZeneca
12.20 Networking Lunch
KEYNOTE ADDRESS
1.30 Considerations on advancing a novel analgesic pipeline
The current set of analgesics available to patients has been
inadequate to manage chronic pain. The inadequacies stem
from both insufficient efficacy, as well as substantial risks in
these analgesics use for chronic pain. Development of novel,
non-opioid analgesics that match the safety and efficacy
requirements of indications improves the drugs’ utility and
likelihood of technical success
• Risk: Benefit in matching drug and target to appropriate
indications and populations
• Utility of Big Data analytics in identifying indications for
novel analgesics
• Case Study of CNTX-4975 development in Morton’s
Neuroma and Knee Osteoarthritis
Dr Randall Stevens, Chief Medical Officer,
Centrexion Therapeutics Corp.
2.10 Using patient reported outcome measures to improve the
management of pain (PROMs)
• Use of PROMs in patient management and clinical trials
in pain
• Correlation of baseline characteristics and PROMs for
specific pain conditions- available evidence
• New IMI2 call will help enhance use of PROMs in the
management of different pain conditions as well as in
pain research
Dr Shaloo Pandhi, Global Program Medical Director, Novartis
2.50 Afternoon Tea
3.20 Drug development to patients: What does the road look like?
• Therapy areas and patient selection
• Market and marketing
• Legislation and access
Dr Karin Hygge Blakeman, Head of Medical Affairs Nordics,
Grunenthal Sweden AB
4.00 Potassium channels as pain and migraine targets:
Challenges and path forward
• Nociceptive pathways
• K+ channels and pain signalling
• Voltage-gated K+ channels
• Two pore domain channels
Dr Narender Gavva, Scientific Director, Amgen
4.40 Chairman’s Closing Remarks and Close of Day Two
THERAPEUTIC APPROACHES AND MODELS
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING OPPORTUNITIES
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email: tarri@smi-online.co.uk
Supported by

4. Animal Models of Pain:
A Critical Assessment
Overview of the workshop:
The purpose of this workshop is to educate the audience on
the various animal models used to evaluate analgesic drugs.
Strengths, weakness and the clinical relevance of the models
will be described with an emphasis on pain associated with
osteoarthritis. Pain will be defined as a phenomenon and with
regardtosite,modality,electrophysiology,neuronalplasticityand
affective state. The utility of pain biomarkers and their relationship
to PK/PD will be introduced along with relevant drug targets and
mechanisms.
Why should you attend this workshop:
• To understand the pain phenomenon from a molecular to a
clinical perspective
• To understand what pain models appropriate for the drug
target and mechanism of interest
• To make informed decisions on which models to invest in for
efficacy proof of concept for novel analgesic drugs
• If you are particularly interested in how best to assess the
efficacy and safety of a novel analgesic for the treatment of
osteoarthritic pain
Programme
08.30 Registration & Coffee
09.00 Opening remarks and introductions
09.10 Defining the pain phenomenon
• Understanding pain associated with anatomical
site, disease pathology, and its duration
• Clinical pain states, the role of inflammation, pain
mediators
• Peripheral and central sensitization
09.50 Animal models and pain
• Models of spontaneous and evoked pain
• Models of neuropathic, visceral, and cancer pain
• Models of affective pain behaviours
• Drugs active in these models; why and why not
10.30 Morning Coffee
11.00 Focus on osteoarthritis pain
• Models of pain associated with osteoarthritis
• Interpretation of efficacy and safety data
• Relevance of animal models to human clinical
pain states
• Analgesics that translate between human and
animal pain models
11.40 Current approach to use pain biomarkers
• Pain biomarkers and their relationship to disease
• Pain biomarkers and the effects of analgesics: PK/PD
• Relevance of pain biomarkers in experimental
and human clinical pain states
12.20 Closing remarks
12.30 End of workshop
About the workshop leader:
Steve is a Registered Pharmacist and received his Pharmacy
degree from Drake University. He then pursued graduate studies
in Pharmacology and received a PhD from the College of
MedicineattheUniversityofIllinois. Stevebecameapostdoctoral
fellow in Pharmacology at the University of Kentucky, College
of Medicine from, later becoming a Research Associate in
Veterinary Sciences. His research at the time focused on in
vivo neuropharmacology of pain transmission and opioid and
nicotine pharmacology. Subsequently, Steve joined the faculty
of the School of Veterinary Medicine at Louisiana State University
and achieved the rank of Endowed Professor at the time of his
departure. He subsequently joined the Pharmacia & Upjohn
Company (later becoming Pfizer then Zoetis) to pursue a career
in drug discovery and has continued in that capacity since 1999.
Steve is currently Therapeutic Area Head of Pain & Inflammation,
Oncology, Cardiac Disease and Oncology. Steve’s research
interests include animal models of pain, arthritis, inflammation,
heartdiseaseandthepharmacologyofnovelanalgesics,NSAIDs,
opioids and sedatives. He has also been active in evaluating
novel, molecularly targeted therapeutics in spontaneous canine
neoplasias, from a translational medicine perspective. Steve
enjoys playing jazz guitar and singing in his free time.
About the organisation:
Zoetis discovers, develops, manufactures and
commercializes a diverse portfolio of animal
health medicines and vaccines designed
to meet the real-world needs of veterinarians and the livestock
farmers and companion animal owners they support. With
its more than 60 years of experience in animal health, Zoetis
generated $4.8 billion in revenue in 2015 and sells products in over
100 countries. There are approximately 9000 Zoetis colleagues,
with approximately 1,050 in Research and Development, and
approximately 2800 field force members. www.zoetis.com
Workshop Leader: Dr Steven G. Kamerling,
Senior Research Director and Therapeutic Area Head
for Pain, Inflammation, Oncology and Cardiac Disease,
Global Therapeutics Research, Zoetis
HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 24th May 2017
08.30 – 12.30
Copthorne Tara Hotel, London, UK

5. SCIENTIFIC ADVISORY BOARD
FOR 2017
Steven G. Kamerling, RPh, PhD,
Research Fellow and Therapeutic
Area Head for Pain, Inflammation
and Oncology, Global Therapeutics
Research, Veterinary Medicine Research
and Development, Zoetis
Steve joined the Pharmacia & Upjohn Company
(subsequently, Pfizer then Zoetis) in 1999 to pursue a
career in drug discovery and has continued in that
capacity ever since. Steve is currently Therapeutic
Area Head of Pain & Inflammation, Cardiac Disease
and Oncology. Steve’s research interests include
large animal models of pain, arthritis, inflammation,
heart disease and the pharmacology of NSAIDs,
opioids and sedatives. He has also been active
in evaluating novel, molecularly targeted
therapeutics in spontaneous canine neoplasias,
from a translational medicine perspective.
Joseph W. Stauffer, DO, MBA,
Chief Medical Officer,
Cara Therapeutics, Inc.
Joe is also the Founder of Alta Life Sciences, LLC,
a boutique pharmaceutical/investment consulting
firm. He is a 2002 founding member of the Initiative
on Methods, Measurement and Pain Assessment in
Clinical Trials (IMMPACT). In 2011, under the FDA’s
Critical Path Initiative, this collaboration became an
official public-private partnership between pharma,
FDA, NIH, academia and patient advocacy
associations. In 2005 he served as an expert
member of the FDA/Mayo Clinic Working group on
Patient Reported Outcomes and co-authored the
supportive paper (Value in Health, Nov/Dec 2007)
on validation of self-reported outcome measures. In
2007 he was named one of the “100 Most Inspiring
People” by PharmaVOICE magazine. In 2011 he
was selected as a Board member of the American
Academy of Pain Medicine Foundation. In 2014
he was appointed to the Board of Directors of
TrialScope, a provider of technology enhanced
clinical trial solutions and services.
Professor Anthony Jones,
Professor of Neuro-Rheumatology,
University of Manchester
Anthony Jones is professor of Neuro-rheumatology
at Manchester University and leads the Human Pain
Research Group. He is a consultant rheumatologist
at Salford Royal Foundation Trust. He has established
one of the first multidisciplinary inflammatory arthritis
clinics in the North West for patients with complex
needs. Over the last twenty years he has used a
number of functional brain imaging techniques to
understand the normal and abnormal mechanisms
of pain perception. He also leads the International
Association for the Study of Pain Musculoskeletal
Pain Taskforce, and has led the development
of National and International Guidelines on the
Integrated Management of Musculoskeletal Pain
(jointly sponsored by the BSR and the IASP). His main
current goals are to use the current understanding
of pain perception to encourage more rational
use of current therapies and to develop new
mechanisms-based treatments for pain.
Pain Therapeutics
www.pain-therapeutics.co.uk
Register online at
www.pain-therapeutics.co.uk
Alternatively fax your registration
to +44 (0)870 9090 712
or call +44 (0)870 9090 711

6. Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-207 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
EARLY BIRD
DISCOUNT
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-207
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SY London
PAIN THERAPEUTICS
Conference: Monday 22nd & Tuesday 23rd May 2017, Copthorne Tara Hotel, London, UK Workshop: Wednesday 24th May 2017, London, UK
4 WAYS TO REGISTER
www.pain-therapeutics.co.uk
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK
□ Book by 31st January to receive £400 off the conference price
□ Book by 28th February to receive £200 off the conference price
□ Book by 31st March to receive £100 off the conference price
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ Workshop only £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.